AUTLAutolus Therapeutics plc

AUTL Stock Price, Valuation & Chart | Autolus Therapeutics plc

Compare

$2.240-0.07 (-3.03%)

At close · 02 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology AUTL intrinsic value AUTL calculated fair value vs price

Overview Financials Dividends Ratios

AUTL Historical price chart

AUTL Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization596.16M

PE Ratio-2.06

EPS-1.09

Trading Volume2.31M

Today's High/Low2.38/2.22

Dividend Yield0.00

52 Week High/Low2.58/1.18

Shares Outstanding266.14M

AUTL Financial Statement

AUTL Analyst ratings

AUTL Analysis & performance metrics

AUTL Company profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include…

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in…

AUTL Management team

Name

Position

Alexander Swan

Senior Vice President & Chief Human Resources Officer

Christopher Williams

Chief Business Officer

Martin Pule M.D., MBBS

Founder, Senior Vice President & Chief Scientific Officer

Matthias Will M.D.

Senior Vice President & Chief Development Officer

Olivia ManserCTO

Director of Investor Relations

Christian Martin Itin Ph.D.CEO

Chief Executive Officer & Director

Christopher VannCOO

Senior Vice President & Chief Operating Officer

Alex Driggs

Senior Vice President of Legal Affairs & General Counsel and Secretary

Name

Position

Alexander Swan

Senior Vice President & Chief Human Resources Officer

Christopher Williams

Chief Business Officer

Martin Pule M.D., MBBS

Founder, Senior Vice President & Chief Scientific Officer

Matthias Will M.D.

Senior Vice President & Chief Development Officer

Olivia ManserCTO

Director of Investor Relations

Christian Martin Itin Ph.D.CEO

Chief Executive Officer & Director

Christopher VannCOO

Senior Vice President & Chief Operating Officer

Alex Driggs

Senior Vice President of Legal Affairs & General Counsel and Secretary

Management Team

Alexander Swan

Senior Vice President & Chief Human Resources Officer

Christopher Williams

Chief Business Officer

Martin Pule M.D., MBBS

Founder, Senior Vice President & Chief Scientific Officer

Matthias Will M.D.

Senior Vice President & Chief Development Officer

Olivia ManserCTO

Director of Investor Relations

Christian Martin Itin Ph.D.CEO

Chief Executive Officer & Director

Christopher VannCOO

Senior Vice President & Chief Operating Officer

Alex Driggs

Senior Vice President of Legal Affairs & General Counsel and Secretary

Management

Alexander Swan

Senior Vice President & Chief Human Resources Officer

Christopher Williams

Chief Business Officer

Martin Pule M.D., MBBS

Founder, Senior Vice President & Chief Scientific Officer

Matthias Will M.D.

Senior Vice President & Chief Development Officer

Olivia ManserCTO

Director of Investor Relations

Christian Martin Itin Ph.D.CEO

Chief Executive Officer & Director

Christopher VannCOO

Senior Vice President & Chief Operating Officer

Alex Driggs

Senior Vice President of Legal Affairs & General Counsel and Secretary

Total 8 executives

AUTL Frequently asked questions

What is Autolus Therapeutics plc (AUTL) Stock Price?

Current stock price of Autolus Therapeutics plc (AUTL) stock is $2.240. The stock price is -3.03% lower in the session. The intraday range can be seen from this page. Volume of Autolus Therapeutics plc (AUTL) stock is 2.31M.

Last updated at 02 Sept 2026, 08:00 pm.

Why is the Autolus Therapeutics plc (AUTL) stock price going up or down today?

The stock price of Autolus Therapeutics plc (AUTL) can change with earnings, company news, and overall market sentiment. Autolus Therapeutics plc operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Autolus Therapeutics plc stock expensive at its current price?

Whether Autolus Therapeutics plc looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for AUTL on this page is -2.06. EPS on this page is -1.09. Compare those figures with peers and growth expectations before deciding if the current Autolus Therapeutics plc price is justified.

How has the stock price of Autolus Therapeutics plc (AUTL) performed historically?

Historical performance for Autolus Therapeutics plc (AUTL) is shown on the price chart on this page. Review multi-period moves alongside volume to see how AUTL reacted to past earnings and market events.

Should I buy Autolus Therapeutics plc (AUTL) stock, at this price?

Buying Autolus Therapeutics plc (AUTL) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.